描述早期症状性阿尔茨海默病的临床异质性:一个数据驱动的机器学习方法
Xiwu Wang1, Teng Ye2, Deguo Jiang1
1Department of Psychiatry, Wenzhou Seventh People's Hospital, Wenzhou, China.
Frontiers in aging neuroscience
|August 28, 2024
概括
阿尔茨海默病显示出各种认知能力的下降. 研究人员确定了4个不同进展率的患者群,帮助未来的阿尔茨海默病治疗临床试验设计.
科学领域:
- 神经科学是一个神经科学.
- 临床神经学 临床神经学
- 生物统计学 生物统计学
背景情况:
- 阿尔茨海默病 (AD) 在临床进展和神经生物学上表现出显著的异质性.
- 粉样蛋白沉积与认知能力下降有关,但早期的AD异质性仍然不清楚.
研究的目的:
- 调查临床异质性,并确定早期症状性阿尔茨海默病的认知亚型.
- 分析认知轨迹和相关的临床/生物标志物变化在一个良好的特征队列.
主要方法:
- 从421名阿尔茨海默氏病神经成像倡议参与者的ADAS-Cog-13数据的纵向聚类分析.
- 在已识别的集群中分析认知,功能和神经退行症标志物.
- 开发一种名图来预测急剧认知衰退.
主要成果:
- 在早期阿兹海默症患者中发现了四种不同的认知进展群.
- 在集群之间观察到临床进展,功能结果和神经退行症标志物的显著差异.
- 对于度认知轨迹的预测性诺米图显示出高准确性 (AUC=0.912) 和减少临床试验样本大小的潜力.
结论:
- 基于认知轨迹的患者分层在AD早期是可行的.
- 识别不同的认知亚型可以提高未来阿尔茨海默病临床试验的效率.
- 这种方法可以提高检测有效治疗方法的可能性.
相关概念视频
Alzheimer's Disease: Overview
456
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
456
Dementia
107
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
107
Alzheimer's Disease: Treatment
170
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
170


